Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Argent BiopharmaRGTLF Cash-to-Debt is 0.17 as of Dec. 2025, which is 80% below its 10-year median of 0.86. The stock has 8 warning signs investors should review. Among 964 Drug Manufacturers companies, Argent Biopharma ranks worse than 79.15% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Argent Biopharma's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.17.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Argent Biopharmacouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Argent Biopharma's Cash-to-Debt or its related term are showing as below:
RGTLF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.86 Max: No Debt
Current: 0.17
During the past 13 years, Argent Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 0.86.
RGTLF's Cash-to-Debt is ranked worse than 79.15% of 964
companies
in the Drug Manufacturers industry
Industry Median: 0.97
vs RGTLF: 0.17
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Argent Biopharma Cash-to-Debt Related Terms
Argent Biopharma Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (RGTLF) has a Cash-to-Debt of 0.17 as of Dec. 2025. This is 80% below median its historical median of 0.86. Over the past decade, Argent Biopharma's Cash-to-Debt has ranged from 0.08 to 10,000.00. According to the industry distribution chart, Argent Biopharma ranks #763 out of 964 companies in the Drug Manufacturers industry, placing it in the top 79.1%.
Is Argent Biopharma's Cash-to-Debt too high?
Argent Biopharma's current Cash-to-Debt of 0.17 is 80% below median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.97. Argent Biopharma's value of 0.17 is 82.5% below this industry median. Based on the distribution chart, Argent Biopharma ranks #763 out of 964 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #763 out of 964 companies for Cash-to-Debt. This places Argent Biopharma in the lower half of its industry. The industry median Cash-to-Debt is 0.97. Argent Biopharma's value of 0.17 is 82.5% below this benchmark. Historically, Argent Biopharma's own Cash-to-Debt has ranged from 0.08 to 10,000.00 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 0.97, Argent Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Argent Biopharma's current Cash-to-Debt of 0.17 is 82.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current Cash-to-Debt is 0.17, which is 80% below median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 72.5% below its estimated fair value. The current Cash-to-Debt is 0.17, which is 80% below median its 10-year median of 0.86 and 82.5% below the Drug Manufacturers industry median of 0.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Cash-to-Debt is 0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 
